The Medipattern Corporation V.MKI

News..

[EDDY05]

TORONTO, ONTARIO--(Marketwire - May 30, 2011) - The Medipattern Corporation ("Medipattern")(TSX VENTURE:MKI), a pioneer in the development of imaging software solutions that help medical practitioners better understand lesions and critical anatomy, today announced its financial results for its third fiscal quarter of 2011 ended March 31, 2011.
Jeff Collins, CEO of Medipattern, commented "The third quarter of fiscal 2011 was significant for Medipattern as we received US FDA clearance for our new Visualize:Vascular(TM) 3D vascular ultrasound imaging product. Subsequent to successfully receiving our FDA clearance, we completed a $3 million financing to support fine tuning of the product, the initial limited launch over the summer and the scheduled full commercial roll-out into the vascular market in the fall of this year. Our focus in the near term will be to continue to capitalize on the exceptional industry response Visualize:Vascular(TM)has generated through initial testing. The technology is proving to be clinically valued by vascular surgeons, radiologists and cardiologists."
Collins also remarked, "The results from the next clinical study using the 3D rendering feature provided by Visualize:Vascular(TM)are planned to be presented at the Annual Vascular meeting which is the joint annual meeting for the Society for Vascular Surgeons and the Society for Vascular Ultrasound from June 16 to 18 in Chicago. The paper, "Three Dimensional Reconstruction of the Vessel Lumen as an Adjunct to the Cerebrovascular Duplex Evaluation" by Francis J. Porreca, MD, FACS, RPVI, Angela Rodriguez-Wong, MD, RVT, RPVI, and Joseph P. Hughes, RVT, RVS will be presented at that time. We believe the product launch will be amplified through substantiated clinical benefits and have directed our efforts toward sponsoring investigations with clinical research partners," Collins concluded.
Medipattern Reports Unaudited Results for Q3 2011